Last reviewed · How we verify
Zunrisa (CASOPITANT)
Zunrisa (generic name: CASOPITANT) is a casopitant drug. It is currently in Phase 3 development.
Zunrisa works by blocking the action of Substance-P, a natural substance that can cause nausea and vomiting.
Zunrisa (casopitant) is a small molecule drug that targets the Substance-P receptor. It is a member of the drug class casopitant and works by blocking the action of Substance-P, a natural substance in the body that can cause nausea and vomiting. Zunrisa is not FDA-approved for any indications, and its commercial status is unknown. Key safety considerations include its half-life of 15.6 hours, although its bioavailability and off-patent status are unknown.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CASOPITANT |
|---|---|
| Drug class | casopitant |
| Target | Sigma non-opioid intracellular receptor 1, Substance-P receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 3 |
Mechanism of action
Imagine your body has a natural 'message' system that helps you feel sick when you're about to vomit. Substance-P is one of these messages, and it's sent to your brain to make you feel nauseous. Zunrisa blocks this message, helping to prevent nausea and vomiting.
Approved indications
Common side effects
Key clinical trials
- A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. (PHASE3)
- Cyclophosphamide Drug Interaction Study In Cancer Patients (PHASE1)
- A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults (PHASE1)
- Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment (PHASE1)
- A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant). (PHASE1)
- Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769] (PHASE1)
- A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy (PHASE3)
- A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zunrisa CI brief — competitive landscape report
- Zunrisa updates RSS · CI watch RSS
Frequently asked questions about Zunrisa
What is Zunrisa?
How does Zunrisa work?
What is the generic name of Zunrisa?
What drug class is Zunrisa in?
What development phase is Zunrisa in?
What does Zunrisa target?
Related
- Drug class: All casopitant drugs
- Target: All drugs targeting Sigma non-opioid intracellular receptor 1, Substance-P receptor
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing